New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth

PURPOSE: Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer properties, however, it causes systemic lymphop...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Breast Cancer Res Treat
Prif Awduron: Alshaker, Heba, Wang, Qi, Srivats, Shyam, Chao, Yimin, Cooper, Colin, Pchejetski, Dmitri
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer US 2017
Pynciau:
Preclinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5602005/
https://ncbi.nlm.nih.gov/pubmed/28695300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4380-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg